64 related articles for article (PubMed ID: 8363442)
1. Poor tolerability of MK-458.
Cutler NR; Sramek JJ; Block GA
Arch Neurol; 1993 Sep; 50(9):896. PubMed ID: 8363442
[No Abstract] [Full Text] [Related]
2. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Koller WC; Block GA; Ahlskog JE; Ahrens S; Cedarbaum JM; Cyhan G; Goetz CG; LeWitt PA; Liss C; McLean L
Clin Neuropharmacol; 1991 Aug; 14(4):322-9. PubMed ID: 1913699
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic agonists in the treatment of Parkinson's disease.
Goetz CG; Diederich NJ
Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
[TBL] [Abstract][Full Text] [Related]
4. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).
Ahlskog JE; Muenter MD; Bailey PA; Stevens PM
Arch Neurol; 1992 May; 49(5):560-8. PubMed ID: 1580821
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
Cutler NR; Reines SA; McLean LF; Sramek JJ; Porras AG; Hand EL
Clin Pharmacokinet; 1992 Mar; 22(3):223-30. PubMed ID: 1348452
[TBL] [Abstract][Full Text] [Related]
6. NMR imaging investigations of drug delivery devices using a flow-through USP dissolution apparatus.
Fyfe CA; Grondey H; Blazek-Welsh AI; Chopra SK; Fahie BJ
J Control Release; 2000 Jul; 68(1):73-83. PubMed ID: 10884581
[TBL] [Abstract][Full Text] [Related]
7. Hydroxypropylmethylcellulose, viscosity, and plasma cholesterol control.
Topping D
Nutr Rev; 1994 May; 52(5):176-8. PubMed ID: 8052459
[TBL] [Abstract][Full Text] [Related]
8. Effect of FITC-dextran molecular weight on its release from floating cetyl alcohol and HPMC tablets.
Xu G; Groves MJ
J Pharm Pharmacol; 2001 Jan; 53(1):49-56. PubMed ID: 11206192
[TBL] [Abstract][Full Text] [Related]
9. The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation.
McConville JT; Ross AC; Chambers AR; Smith G; Florence AJ; Stevens HN
Eur J Pharm Biopharm; 2004 May; 57(3):541-9. PubMed ID: 15093604
[TBL] [Abstract][Full Text] [Related]
10. Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component.
Kiortsis S; Kachrimanis K; Broussali T; Malamataris S
Eur J Pharm Biopharm; 2005 Jan; 59(1):73-83. PubMed ID: 15567304
[TBL] [Abstract][Full Text] [Related]
11. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation.
Huang YB; Tsai YH; Yang WC; Chang JS; Wu PC; Takayama K
Eur J Pharm Biopharm; 2004 Nov; 58(3):607-14. PubMed ID: 15451535
[TBL] [Abstract][Full Text] [Related]
12. Protection of corneal endothelium from irrigation damage: a comparison of sodium hyaluronate and hydroxypropylmethylcellulose.
Dua HS; Benedetto DA; Azuara-Blanco A
Eye (Lond); 2000 Feb; 14 ( Pt 1)():88-92. PubMed ID: 10755108
[TBL] [Abstract][Full Text] [Related]
13. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances.
Sangalli ME; Maroni A; Foppoli A; Zema L; Giordano F; Gazzaniga A
Eur J Pharm Sci; 2004 Aug; 22(5):469-76. PubMed ID: 15265517
[TBL] [Abstract][Full Text] [Related]
14. Oxidative tissue damage after phacoemulsification: influence of ophthalmic viscosurgical devices.
Augustin AJ; Dick HB
J Cataract Refract Surg; 2004 Feb; 30(2):424-7. PubMed ID: 15030835
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose.
Maki KC; Davidson MH; Malik KC; Albrecht HH; O'Mullane J; Daggy BP
Am J Cardiol; 1999 Nov; 84(10):1198-203. PubMed ID: 10569330
[TBL] [Abstract][Full Text] [Related]
16. Controlled release of carbamazepine from pellets and tablets manufactured with hydroxypropyl methylcellulose.
Qadan A; Süss W
Pharmazie; 2000 Aug; 55(8):628. PubMed ID: 10989848
[No Abstract] [Full Text] [Related]
17. A study of the spread surface of polymeric dispersions of Eudragit.
Lucero MJ; Garcia-Andreu J; Roman F; Leon MJ
Drug Dev Ind Pharm; 2000 Jul; 26(7):797-801. PubMed ID: 10872102
[TBL] [Abstract][Full Text] [Related]
18. An animal model based on the Sprague Dawley rat for the evaluation of ototoxicity.
Martini A; Hatzopoulos S; Rubini R; Di Stefano M; Albertin A; Govoni E
Ann N Y Acad Sci; 1999 Nov; 884():85-98. PubMed ID: 10842586
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets.
Ghimire M; Hodges LA; Band J; O'Mahony B; McInnes FJ; Mullen AB; Stevens HN
J Control Release; 2010 Oct; 147(1):70-5. PubMed ID: 20600400
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca.
Nelson JD; Drake MM; Brewer JT; Tuley M
Adv Exp Med Biol; 1994; 350():453-7. PubMed ID: 8030518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
